Vivani Medical (VANI)
NASDAQ:VANI
VANI Stock Chart & Stats
$1.28
-$0.02(-1.59%)
At close: 4:00 PM EST
$1.28
-$0.02(-1.59%)
Day’s Range― - ―
52-Week Range$0.92 - $1.92
Previous CloseN/A
Volume36.09K
Average Volume (3M)216.92K
Market Cap
$89.73M
Enterprise Value$65.25M
Total Cash (Recent Filing)$16.23M
Total Debt (Recent Filing)$18.86M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding84,647,804
10 Day Avg. Volume237,036
30 Day Avg. Volume216,922
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.88
Price to Sales (P/S)0.00
P/FCF Ratio-3.01
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-296.57
Enterprise Value/Ebitda-2.41
Forecast
1Y Price Target
$3.75Price Target Upside192.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPlanned Phase 1 trial for NPM-139 could establish human safety, tolerability and drug behavior, guiding design of later efficacy studies and increasing development clarity.
Efficacy And Tolerability ProfilePreclinical durable weight-loss signals and indications of improved tolerability versus marketed semaglutide therapies could reduce discontinuation and strengthen competitive positioning.
Patient Adherence And ConvenienceSubdermal semaglutide implant designed for infrequent dosing could improve convenience and adherence compared with frequent injections, supporting broader patient uptake.
Bears Say
Asset Monetization ConstraintA post-IPO lock-up on Cortigent shares would restrict near-term monetization of that asset and could limit short-term financing flexibility.
Financing UncertaintyRecent capital raises and the prospect of seeking additional funding indicate potential future financing needs that could dilute shareholders or create execution risk.
Share Dilution RiskAnalyst lowered the price target after an increased share count, highlighting dilution risk that can pressure per-share valuation.
Vivani Medical News
VANI FAQ
What was Vivani Medical’s price range in the past 12 months?
Vivani Medical lowest stock price was $0.92 and its highest was $1.92 in the past 12 months.
What is Vivani Medical’s market cap?
Vivani Medical’s market cap is $89.73M.
When is Vivani Medical’s upcoming earnings report date?
Vivani Medical’s upcoming earnings report date is May 18, 2026 which is in 38 days.
How were Vivani Medical’s earnings last quarter?
Vivani Medical released its earnings results on Mar 26, 2026. The company reported -$0.09 earnings per share for the quarter, the consensus estimate of -$0.09 by $0.
Is Vivani Medical overvalued?
According to Wall Street analysts Vivani Medical’s price is currently Undervalued.
Does Vivani Medical pay dividends?
Vivani Medical does not currently pay dividends.
What is Vivani Medical’s EPS estimate?
Vivani Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivani Medical have?
Vivani Medical has 84,647,804 shares outstanding.
What happened to Vivani Medical’s price movement after its last earnings report?
Vivani Medical reported an EPS of -$0.09 in its last earnings report, expectations of -$0.09. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of Vivani Medical?
Currently, no hedge funds are holding shares in VANI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vivani Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.75 (192.97% Upside)
$3.75 (192.97% Upside)
Insider Transactions
Bought Shares
Worth $7.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.12%
12-Months-Change
Fundamentals
Return on Equity
-317.03%
Trailing 12-Months
Asset Growth
-0.07%
Trailing 12-Months
Company Description
Vivani Medical
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
VANI Stock 12 Month Forecast
Average Price Target
$3.75
▲(192.97% Upside)
Technical Analysis
Ownership Overview
56.36% Insiders
2.19% Mutual Funds
1.52% Other Institutional Investors
38.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---